Eversept Partners, LP
13F Reported Value
ⓘ$1.9B
incl. option notional
Equity Holdings
ⓘ$1.8B
Option Notional
ⓘ$93.3M
$80.3M puts / $13.0M calls
Holdings
120
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Eversept Partners, LP disclosed 120 positions worth $1.9B in its Form 13F-HR for Q2 2026 — $1.8B in common stock plus $93.3M of put/call option positions (reported at underlying notional value, not premium at risk), led by $UTHR (UNITED THERAPEUTICS Corp) at 8.5% of the equity portfolio, followed by $ABVX and $EHC. During the quarter the fund opened 31 new positions and exited 31 — including a new stake in $CTRE and a full exit from $SPY. The portfolio is most concentrated in Healthcare (92.0% of disclosed assets). All figures are sourced directly from Eversept Partners, LP’s Form 13F-HR filing with the SEC under CIK 1697013.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 71.3#189
Quality
$155.9M287,668 sh - —
Quality
$121.8M913,880 sh - 66.9#388
Quality
$103.8M1,026,919 sh - 67.9
Quality
$96.5M602,079 sh - —
Quality
$94.9M2,212,770 sh - $72.6M98,600 sh
- 8.4
Quality
$66.5M1,785,941 sh - 33.8
Quality
$61.2M2,798,210 sh - 44.1
Quality
$54.6M3,396,470 sh - 23.4
Quality
$52.7M664,684 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 UNITED THERAPEUTICS Corp$UTHR | 71.3#189 | $155.9M | 287,668 |
 Abivax S.A.$ABVX | — | $121.8M | 913,880 |
 Encompass Health Corp$EHC | 66.9#388 | $103.8M | 1,026,919 |
 ENSIGN GROUP, INC$ENSG | 67.9 | $96.5M | 602,079 |
 Vera Therapeutics, Inc.$VERA | — | $94.9M | 2,212,770 |
 INVESCO QQQ TRUST, SERIES 1$QQQPUT | — | $72.6M | 98,600 |
 Celldex Therapeutics, Inc.$CLDX | 8.4 | $66.5M | 1,785,941 |
 Syndax Pharmaceuticals Inc$SNDX | 33.8 | $61.2M | 2,798,210 |
 Brookdale Senior Living Inc.$BKD | 44.1 | $54.6M | 3,396,470 |
 IONIS PHARMACEUTICALS INC$IONS | 23.4 | $52.7M | 664,684 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Eversept Partners, LP's 120 positions.
Showing top 10 of 120 holdings.
Sector Allocation
Healthcare
$1.7B
Real Estate
$107.7M
Technology
$24.6M
Industrials
$13.9M
Financials
$872,206
Full Holdings — Eversept Partners, LP (Q2 2026)
All 120 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $UTHR | UNITED THERAPEUTICS Corp | $155.9M | 8.5% | +9% | 71.3 |
| 2 | $ABVX | Abivax S.A. | $121.8M | 6.6% | -2% | — |
| 3 | $EHC | Encompass Health Corp | $103.8M | 5.7% | +429% | 66.9 |
| 4 | $ENSG | ENSIGN GROUP, INC | $96.5M | 5.3% | +3979% | 67.9 |
| 5 | $VERA | Vera Therapeutics, Inc. | $94.9M | 5.2% | +2% | — |
| 6 | $QQQPUT | INVESCO QQQ TRUST, SERIES 1 | $72.6M | — | -59% | — |
| 7 | $CLDX | Celldex Therapeutics, Inc. | $66.5M | 3.6% | -0% | 8.4 |
| 8 | $SNDX | Syndax Pharmaceuticals Inc | $61.2M | 3.3% | -3% | 33.8 |
| 9 | $BKD | Brookdale Senior Living Inc. | $54.6M | 3.0% | -5% | 44.1 |
| 10 | $IONS | IONIS PHARMACEUTICALS INC | $52.7M | 2.9% | +5% | 23.4 |
| 11 |  $NTRA | Natera, Inc. | $47.7M | 2.6% | -54% | 53.5 |
| 12 |  $TVTX | Travere Therapeutics, Inc. | $45.4M | 2.5% | +47% | 56.6 |
| 13 |  $CTRE | CareTrust REIT, Inc. | $43.3M | 2.4% | NEW | 74.1 |
| 14 |  $HCA | HCA Healthcare, Inc. | $38.3M | 2.1% | +24% | 68.9 |
| 15 |  $PCVX | Vaxcyte, Inc. | $36.6M | 2.0% | -32% | — |
| 16 |  $LQDA | Liquidia Corp | $34.2M | 1.9% | -37% | 78.3 |
| 17 |  $CYH | COMMUNITY HEALTH SYSTEMS INC | $26.3M | 1.4% | -9% | 49.6 |
| 18 |  $GSK | GSK plc | $25.3M | 1.4% | -73% | — |
| 19 |  $CHE | CHEMED CORP | $24.5M | 1.3% | +69% | 62.9 |
| 20 |  $LLY | ELI LILLY & Co | $24.1M | 1.3% | +6% | 87.5 |
| 21 |  $GERN | GERON CORP | $24.0M | 1.3% | -1% | — |
| 22 |  $VKTX | Viking Therapeutics, Inc. | $23.5M | 1.3% | +152% | — |
| 23 |  $OHI | OMEGA HEALTHCARE INVESTORS INC | $23.1M | 1.3% | -17% | 56.5 |
| 24 |  $PODD | INSULET CORP | $22.7M | 1.2% | +4% | 71.3 |
| 25 |  $THC | TENET HEALTHCARE CORP | $21.4M | 1.2% | +287% | 66.2 |
| 26 |  $UNH | UNITEDHEALTH GROUP INC | $21.3M | 1.2% | NEW | 62.7 |
| 27 |  $WELL | WELLTOWER INC. | $19.8M | 1.1% | -52% | 59.8 |
| 28 |  $BBNX | Beta Bionics, Inc. | $19.6M | 1.1% | -12% | 29.8 |
| 29 |  $COGT | Cogent Biosciences, Inc. | $19.0M | 1.0% | NEW | — |
| 30 |  $BCRX | BIOCRYST PHARMACEUTICALS INC | $18.7M | 1.0% | -39% | 53.2 |
| 31 |  $MOH | MOLINA HEALTHCARE, INC. | $18.4M | 1.0% | +146% | 56.5 |
| 32 |  $PNTG | Pennant Group, Inc. | $17.0M | 0.9% | +47% | 62.6 |
| 33 |  $LTC | LTC PROPERTIES INC | $16.2M | 0.9% | +31% | 51 |
| 34 |  $INSM | INSMED Inc | $15.9M | 0.9% | NEW | 39.4 |
| 35 |  $VRDN | Viridian Therapeutics, Inc.\DE | $15.3M | 0.8% | +17% | 27.2 |
| 36 |  $BMRN | BIOMARIN PHARMACEUTICAL INC | $14.3M | 0.8% | +20% | 58.2 |
| 37 |  $AMN | AMN HEALTHCARE SERVICES INC | $13.9M | 0.8% | NEW | 54.5 |
| 38 |  $CELC | Celcuity Inc. | $13.4M | 0.7% | NEW | — |
| 39 |  $PHVS | Pharvaris N.V. | $13.4M | 0.7% | -5% | — |
| 40 |  $CTMX | CytomX Therapeutics, Inc. | $13.3M | 0.7% | +12% | 8.7 |
| 41 |  $HUM | HUMANA INC | $12.4M | 0.7% | NEW | 58.9 |
| 42 |  $XENE | Xenon Pharmaceuticals Inc. | $11.9M | 0.7% | +52% | 24 |
| 43 |  $CRVS | Corvus Pharmaceuticals, Inc. | $11.2M | 0.6% | NEW | — |
| 44 |  $ASND | Ascendis Pharma A/S | $11.1M | 0.6% | NEW | 44.8 |
| 45 |  $BRKR | BRUKER CORP | $11.0M | 0.6% | +56% | 50.8 |
| 46 |  $MRNA | Moderna, Inc. | $10.7M | 0.6% | -5% | 21.2 |
| 47 |  $GPCR | Structure Therapeutics Inc. | $10.5M | 0.6% | +42% | — |
| 48 | $INSMCALL | INSMED Inc | $10.3M | — | +3% | 39.4 |
| 49 |  $DFTX | Definium Therapeutics, Inc. | $10.2M | 0.6% | +35% | — |
| 50 |  $CMPS | COMPASS Pathways plc | $9.5M | 0.5% | -1% | — |
| 51 |  $NAMS | NewAmsterdam Pharma Co N.V. | $9.3M | 0.5% | -4% | — |
| 52 |  $RVTY | REVVITY, INC. | $9.3M | 0.5% | -1% | 57.6 |
| 53 |  $PALI | PALISADE BIO, INC. | $8.7M | 0.5% | -16% | — |
| 54 |  $ARDX | ARDELYX, INC. | $8.6M | 0.5% | -25% | 41.9 |
| 55 |  $MLYS | Mineralys Therapeutics, Inc. | $8.4M | 0.5% | NEW | — |
| 56 |  $RLAY | Relay Therapeutics, Inc. | $8.1M | 0.4% | +60% | 19.5 |
| 57 |  $NVO | NOVO NORDISK A S | $8.1M | 0.4% | NEW | — |
| 58 |  $BHVN | Biohaven Ltd. | $7.7M | 0.4% | NEW | — |
| 59 |  $PTGX | Protagonist Therapeutics, Inc | $7.2M | 0.4% | NEW | 59.4 |
| 60 |  $ELVN | Enliven Therapeutics, Inc. | $6.9M | 0.4% | NEW | — |
| 61 |  $REPL | Replimune Group, Inc. | $6.5M | 0.4% | +76% | — |
| 62 |  $LBRX | LB PHARMACEUTICALS INC | $6.0M | 0.3% | +83% | — |
| 63 |  $BEAM | Beam Therapeutics Inc. | $5.7M | 0.3% | NEW | 34.2 |
| 64 |  $NHI | NATIONAL HEALTH INVESTORS INC | $5.4M | 0.3% | NEW | 71.6 |
| 65 |  $RARE | Ultragenyx Pharmaceutical Inc. | $5.1M | 0.3% | +146% | 34.2 |
| 66 |  $PACS | PACS Group, Inc. | $5.0M | 0.3% | NEW | 71.2 |
| 67 | — | SPDR SERIES TRUST - ST STR SP BIOT | $4.9M | — | +3% | — |
| 68 |  $EQ | Equillium, Inc. | $4.9M | 0.3% | +1% | 11.7 |
| 69 |  $ANAB | ANAPTYSBIO, INC | $4.7M | 0.3% | +158% | 48.4 |
| 70 |  $NHC | NATIONAL HEALTHCARE CORP | $4.7M | 0.3% | NEW | 65.9 |
| 71 |  $EYPT | EyePoint, Inc. | $4.3M | 0.2% | NEW | 3.5 |
| 72 |  $SNDA | SONIDA SENIOR LIVING, INC. | $4.2M | 0.2% | +261% | 43.5 |
| 73 |  $GKOS | GLAUKOS Corp | $4.1M | 0.2% | -51% | 40.5 |
| 74 |  $AGL | agilon health, inc. | $4.1M | 0.2% | -79% | 44.9 |
| 75 |  $ARQT | Arcutis Biotherapeutics, Inc. | $3.5M | 0.2% | -77% | 62.9 |
| 76 |  $TARS | Tarsus Pharmaceuticals, Inc. | $3.5M | 0.2% | NEW | 55 |
| 77 |  $ANRO | Alto Neuroscience, Inc. | $3.4M | 0.2% | +2% | — |
| 78 |  $SPRY | ARS Pharmaceuticals, Inc. | $3.0M | 0.2% | +177% | 20.3 |
| 79 |  $IFRX | InflaRx N.V. | $2.9M | 0.2% | -26% | — |
| 80 |  $ISRG | INTUITIVE SURGICAL INC | $2.9M | 0.2% | -35% | 79.9 |
| 81 |  $ALEC | Alector, Inc. | $2.9M | 0.2% | +5% | 10.9 |
| 82 |  $UHSPUT | UNIVERSAL HEALTH SERVICES INC | $2.8M | — | +3% | 66.7 |
| 83 |  $VOR | Vor Biopharma Inc. | $2.8M | 0.1% | NEW | — |
| 84 |  $DSGN | Design Therapeutics, Inc. | $2.7M | 0.1% | NEW | — |
| 85 |  $KPTI | Karyopharm Therapeutics Inc. | $2.7M | 0.1% | +0% | 15.1 |
| 86 |  $QGENCALL | QIAGEN N.V. | $2.7M | — | -86% | — |
| 87 |  $PMVP | PMV Pharmaceuticals, Inc. | $2.5M | 0.1% | -19% | — |
| 88 |  $CTNM | Contineum Therapeutics, Inc. | $2.4M | 0.1% | +1% | — |
| 89 |  $EVMN | Evommune, Inc. | $2.3M | 0.1% | +219% | 14.9 |
| 90 |  $AMRN | AMARIN CORP PLC\UK | $2.3M | 0.1% | -2% | 31.3 |
| 91 |  $SPRB | SPRUCE BIOSCIENCES, INC. | $2.2M | 0.1% | NEW | — |
| 92 |  $RGEN | REPLIGEN CORP | $2.0M | 0.1% | -88% | 58.4 |
| 93 |  $IVVD | Invivyd, Inc. | $2.0M | 0.1% | -2% | 29.7 |
| 94 |  $PRQR | ProQR Therapeutics N.V. | $1.9M | 0.1% | NEW | — |
| 95 |  $GRCE | Grace Therapeutics, Inc. | $1.8M | 0.1% | +2% | — |
| 96 |  $AVR | Anteris Technologies Global Corp. | $1.6M | 0.1% | -59% | — |
| 97 |  $VIR | Vir Biotechnology, Inc. | $1.6M | 0.1% | -37% | 38.2 |
| 98 |  $EDIT | Editas Medicine, Inc. | $1.5M | 0.1% | +58% | 33.4 |
| 99 |  $WHWK | Whitehawk Therapeutics, Inc. | $1.4M | 0.1% | -1% | 26.4 |
| 100 |  $TECH | BIO-TECHNE Corp | $1.4M | 0.1% | -85% | 58.9 |
| 101 |  $RVMD | Revolution Medicines, Inc. | $1.3M | 0.1% | NEW | — |
| 102 |  $SVRA | Savara Inc | $1.3M | 0.1% | -47% | — |
| 103 |  $SRZN | Surrozen, Inc./DE | $1.2M | 0.1% | -19% | — |
| 104 |  $INO | INOVIO PHARMACEUTICALS, INC. | $1.1M | 0.1% | +0% | 8.3 |
| 105 |  $PLRX | PLIANT THERAPEUTICS, INC. | $1.0M | 0.1% | +0% | — |
| 106 |  $HELP | CYBIN INC. | $967,724 | 0.1% | NEW | — |
| 107 |  $ODTX | Odyssey Therapeutics, Inc. | $929,101 | 0.1% | NEW | — |
| 108 |  $ENGN | enGene Therapeutics Inc. | $812,380 | 0.0% | -8% | — |
| 109 |  $BCYC | BICYCLE THERAPEUTICS PLC | $808,632 | 0.0% | +0% | — |
| 110 |  $LPCN | Lipocine Inc. | $755,172 | 0.0% | +0% | — |
| 111 |  $RLMD | RELMADA THERAPEUTICS, INC. | $644,889 | 0.0% | -66% | — |
| 112 |  $EHTH | eHealth, Inc. | $603,232 | 0.0% | +83% | 52.8 |
| 113 |  $ATAI.R1840904 | Atai Beckley N.V. | $539,806 | 0.0% | NEW | — |
| 114 |  $AKBA | Akebia Therapeutics, Inc. | $486,888 | 0.0% | NEW | 45.3 |
| 115 |  $SSII | SS Innovations International, Inc. | $457,152 | 0.0% | +0% | 30.4 |
| 116 |  $ASMB | ASSEMBLY BIOSCIENCES, INC. | $453,695 | 0.0% | -60% | 41.5 |
| 117 |  $RVP | RETRACTABLE TECHNOLOGIES INC | $418,262 | 0.0% | +0% | 26.9 |
| 118 |  $SLQT | SelectQuote, Inc. | $268,974 | 0.0% | -11% | 54.5 |
| 119 |  $GHRS | GH Research PLC | $233,103 | 0.0% | NEW | — |
| 120 |  $AVTX | Avalo Therapeutics, Inc. | $184,800 | 0.0% | NEW | 11.7 |
New Positions (31)
$CTRE CareTrust REIT, Inc.$43.3M$UNH UNITEDHEALTH GROUP INC$21.3M$COGT Cogent Biosciences, Inc.$19.0M$INSM INSMED Inc$15.9M$AMN AMN HEALTHCARE SERVICES INC$13.9M$CELC Celcuity Inc.$13.4M$HUM HUMANA INC$12.4M$CRVS Corvus Pharmaceuticals, Inc.$11.2M$ASND Ascendis Pharma A/S$11.1M$MLYS Mineralys Therapeutics, Inc.$8.4M$NVO NOVO NORDISK A S$8.1M$BHVN Biohaven Ltd.$7.7M$PTGX Protagonist Therapeutics, Inc$7.2M$ELVN Enliven Therapeutics, Inc.$6.9M$BEAM Beam Therapeutics Inc.$5.7MExited Positions (31)
$SPYPUT SPDR S&P 500 ETF TRUST
$VRTXCALL VERTEX PHARMACEUTICALS INC / MA
$DOC HEALTHPEAK PROPERTIES, INC.
$AVTR Avantor, Inc.$QGEN QIAGEN N.V.$UNHCALL UNITEDHEALTH GROUP INC
$ICLR ICON PLC
$AGIO AGIOS PHARMACEUTICALS, INC.
$MDGL MADRIGAL PHARMACEUTICALS, INC.
$PRAXPUT Praxis Precision Medicines, Inc.
$ESPR Esperion Therapeutics, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Eversept Partners, LP including:
Track Eversept Partners, LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Eversept Partners, LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Eversept Partners, LP
13F Pro is an AI hedge fund tracker and stock research platform. For Eversept Partners, LP (SEC CIK: 1697013), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Eversept Partners, LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.